A nursing instructor is teaching about rivastigmine (Excelon). A student asks, "How does this work? Will this cure Alzheimer's disease (AD)?" Which is the appropriate instructor reply?

A. "This medication delays the destruction of dopamine, a chemical in the brain necessary for memory processes. Although most effective in the early stages, it serves to delay, but not stop, the progression of the AD.": Rivastigmine does not primarily affect dopamine; it targets acetylcholine, which is critical for memory and cognition. Dopamine modulation is more relevant to Parkinson’s disease treatments. B. "This medication encourages production of NMDA, a chemical in the brain necessary for memory processes. It delays the progression of the disease.": NMDA receptors are involved in glutamate signaling, not directly increased by rivastigmine. This description more closely relates to NMDA antagonists like memantine rather than cholinesterase inhibitors. C. "This medication encourages production of acetylcholine, a chemical in the brain necessary for memory processes. It delays the progression of the disease.": Rivastigmine inhibits the breakdown of acetylcholine rather than stimulating its production. The mechanism preserves existing neurotransmitter levels to improve cognitive function. D. "This medication delays the destruction of acetylcholine, a chemical in the brain necessary for memory processes. Although most effective in the early stages, it serves to delay, but not stop, the progression of the AD.": Rivastigmine is a cholinesterase inhibitor that prevents acetylcholine breakdown. This enhances cholinergic neurotransmission, helping maintain cognitive function temporarily, but it does not cure Alzheimer’s disease.